Skip to main content

Macarena Simon-Talero Horga

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Macarena Simon-Talero Horga

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática

IP: Joan Genescà Ferrer
Collaborators: Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 242000
Reference: ICI14/00352
Duration: 01/01/2015 - 30/06/2019

Estudio cirrosis hepática

IP: Joan Genescà Ferrer
Collaborators: Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM14/00220
Duration: 06/04/2015 - 05/04/2017

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Anna Sanjuan Viaplana

Anna Sanjuan Viaplana

Medium Grade Technician
Statistics and Bioinformatics Unit (UEB)
Preclinical Core Facilities
External Strategy Directorate
Read more
Garcia Blanco, Alejandra

Garcia Blanco, Alejandra

Research technician
Neurodegenerative Diseases
Read more
Joan Compte Barrón

Joan Compte Barrón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Piqué Ponti, Julia

Piqué Ponti, Julia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.